Biohaven Pharmaceutical Holding Company Ltd. Stock

$16.25

3.17% yesterday

NYSE, May 20, 10:00 pm CET

ISIN

VGG111961055

Symbol

BHVN

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Biohaven Pharmaceutical Holding Company Ltd. Stock price

$16.25

-35.70 68.72% 5Y

NYSE, Closing price Tue, May 20 2025

+0.50 3.17%

ISIN

VGG111961055

Symbol

BHVN

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$1.66b
Enterprise Value	$1.37b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	6.39
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-923.43m
Free Cash Flow (TTM) Free Cash Flow	$-649.01m
Cash position	$323.85m
EPS (TTM) EPS	$-9.37
P/E forward	negative
P/S forward	135.89
EV/Sales forward	112.28
Short interest	8.64%

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Get Started for Free Today

Biohaven Pharmaceutical Holding Company Ltd. Stock Analysis

Unlock Scores for Free

??

16 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast:

15x Buy

94%

More details on Analyst Estimates Including Price Targets

16 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast:

Buy

94%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Biohaven Pharmaceutical Holding Company Ltd.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	4 4	13% 13% -
Gross Profit	-4 -4	13% 13% -
- Selling and Administrative Expenses	88 88	28% 28% -
- Research and Development Expense	827 827	78% 78% -
EBITDA	-919 -919	71% 71% -
- Depreciation and Amortization	4 4	13% 13% -
EBIT (Operating Income) EBIT	-923 -923	71% 71% -
Net Profit	-889 -889	72% 72% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Biohaven Pharmaceutical Holding Company Ltd. Stock News

Negative

The Motley Fool

●

5 days ago

Why Biohaven Stock Dove by Nearly 20% on Thursday

Volatile biotech stock Biohaven (BHVN -19.41%) is prone to sharp movements both up and down. On Thursday, it had one of its down days, with its share price eroding by almost 20% on a development with a top regulator.

Negative

Investors Business Daily

●

6 days ago

Biohaven Plunges On A Surprise FDA Twist For Its Rare-Disease Drug

Biohaven shares plunged Thursday after the Food and Drug Administration unexpectedly delayed the review date for its rare-disease drug.

Neutral

PRNewsWire

●

6 days ago

FDA Extends PDUFA Date of Biohaven's Troriluzole NDA for Rare Disease Spinocerebellar Ataxia

- Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment. - Troriluzole has been granted Fast-Track, Orphan Drug Designation (ODD) and Priority Review from the FDA.

More Biohaven Pharmaceutical Holding Company Ltd. News

Company Profile

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.

Head office	Virgin Islands, British
CEO	Vladimir Coric
Employees	256
Founded	2022
Website	www.biohaven.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now